Treatment with PI3K inhibitor LY294002 reduced sphere formation [69] while the dual PI3K/mTOR inhibitor NVP-BEZ235 reduced the CD133/AC141+CD44+ cell population in vivo and subsequently delayed tumor formation [117]. This evidence concerns the gene PROM1 and neoplasm.